Program
Anti-PSMA/Anti-4-1BB Bispecific Antibody REGN15505
Also written as “REGN15505”, “REGN15505+Cemiplimab” and “REGN15505+REGN4336”.
Its studies are mostly in Carcinoma, Renal Cell, led by Regeneron Pharmaceuticals.
Furthest: phase 2, since May 11, 20261 company-led study, 1 open or runningNext primary completion: Oct 27, 2030 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Regeneron Pharmaceuticals | 11 open or running | phase 2since May 11, 2026 | May 11, 2026 | Oct 27, 2030phase 2 · NCT07594106 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 11, 2026First study: phase 2 study in Carcinoma, Renal CellFirst studyNCT07594106 · 265 planned · United States
Ahead
- Oct 27, 2030Primary completion: phase 2 study in Carcinoma, Renal CellNCT07594106
TargetBeta
“A bispecific antibody directed against the tumor-associated antigen (TAA) human prostate-specific membrane antigen (PSMA) and the immune co-stimulatory receptor 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), ”NCIt, by rule
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07594106Carcinoma, Renal Cell · United States | 2 | Recruiting | Oct 27, 2030 | 265 |
How it is read
Names in the registry
- “REGN15505”, 1 entry
- “REGN15505+Cemiplimab”, 1 entry
- “REGN15505+REGN4336”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Renal Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.